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Foreword | Project STOP, an online 
database in which pharmacists record 
sales of pseudoephedrine (PSE)-based 
medication, was implemented in 2005 to 
aid in reducing the diversion of PSE-
based products for use as precursors in 
the domestic manufacture of 
methamphetamine. Australian evaluations 
of regulations governing the sale of 
PSE-based medications and the impact 
of Project STOP have so far been limited. 
This research explores the impact of the 
mandatory recording of PSE-based 
medication sales on PSE diversion and 
clan lab detection in Queensland.
The findings show that Project STOP has 
demonstrated its utility for pharmacists in 
determining the legitimacy of requests for 
PSE-based medication, with 95 percent of 
Queensland pharmacies currently using it. 
When used consistently and appropriately, 
Project STOP reduces the amount of 
PSE-based medication leaving 
pharmacies for methamphetamine 
production. The research also highlights 
the challenges of attempting to curtail 
methamphetamine production in Australia 
and suggests new directions for research 
to better address these.
Chris Dawson APM
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The supply of pseudoephedrine (PSE)-based products by pharmacists is regulated 
by national legislation that requires the mandatory electronic recording of PSE-based 
medication sales. First implemented in 2005, Project STOP is an online database that 
allows pharmacists to establish the legitimacy of PSE-based medication sales. This study 
evaluates its utility in reducing the diversion of PSE-based medications to clandestine 
laboratories (clan labs) in Queensland for methamphetamine production. 
The drugs most commonly manufactured in Australian clan labs are amphetamine-type 
stimulants, or ATS (Australian Crime Commission 2013). PSE is the primary precursor 
chemical for manufacturing methamphetamine. A 2009 Siggins Miller review noted that 
law enforcement agencies estimated 90 percent of PSE then used in clan lab manufacture 
was sourced from pharmacies. In 2015, the Australian Crime Commission suggested that 
greater volumes of PSE were being detected at the Australian border, possibly due to 
difficulties sourcing PSE domestically following the implementation of Project STOP.
Background
There are multiple methamphetamine supply chains—the purely domestic and the 
international, which import either precursors or end product, as well as domestic 
manufacture and distribution (Ritter, Bright & Gong 2012). The domestic methamphetamine 
supply chain begins with the acquisition of precursors such as PSE, reagents and 
equipment. This is followed by the manufacture of drugs in predominately small (79%) illicit 
clan labs located in homes or car boots (Schloenhardt 2007) and their wide distribution 
through trafficking networks—interstate, regional and low-level street retail markets—
throughout Australia (Ritter, Bright & Gong 2012). Unlike the United States, where 
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methamphetamine supply is produced by 
larger ‘super-labs’, Australia’s domestic 
methamphetamine supply is smaller in scale 
(Schloenhardt 2007). 
The number of clan labs detected nationally 
has more than doubled over the last 
decade, increasing from 358 in 2003–04 
to 757 in 2012–13 (Unick, Rosenblum, 
Mars & Ciccarone 2014). One reason for 
this increase is that methamphetamine is 
relatively cheap and easy to make, with a 
batch of methamphetamine ready in as little 
as two hours (Weisheit 2008). The necessary 
ingredients are commonly available and 
laboratories can be moved easily and set up 
in other locations (Weisheit 2008).
Strategies to reduce the diversion 
of PSE
A key challenge for Australian police is 
determining which part of the supply chain  
to focus their resources on (Ritter et al. 
2012). Australia’s law enforcement response 
to the domestic methamphetamine supply 
chain problem, like that of many other 
countries, has expanded to focus on 
precursor substances and equipment. Law 
enforcement strategies include partnering 
with pharmacists (Ransley et al. 2012). 
Significant national legislative requirements, 
first implemented in 2006, underpin 
pharmacists’ professional responsibilities 
in the supply of PSE products (Department 
of Health 2010). The Pharmacy Board 
of Australia can suspend a pharmacist’s 
license; it can also take disciplinary action 
against any pharmacist whose dispensing 
practices are in breach of the Queensland 
Health (Drugs and Poisons) Regulation 
1996, or who does not  comply with the 
relevant Pharmaceutical Society of Australia 
Code of Practice (Pharmaceutical Society of 
Australia 2006a, 2006b).
In Queensland, Western Australia, the 
Northern Territory, South Australia and the 
Australian Capital Territory, the electronic 
recording of transactions relating to 
PSE-based medication is mandatory 
(Queensland Health, Pharmacy Guild of 
Australia & Queensland Police Service 2010; 
Sclavos 2013); whereas Victoria, Tasmania 
and New South Wales still operate under a 
voluntary reporting system (McGuffog 2013; 
Ransley et al. 2012). The voluntary reporting 
systems of these states require pharmacists 
to take all reasonable steps to identify the 
purchaser and determine whether the sale 
is legitimate (Ransley et al. 2012). There 
is no legislation requiring that sales be 
reported, or that police be advised of actual 
or suspected illegitimate sales.
Project STOP
Project STOP is an online database in which 
pharmacists record PSE-based medication 
sales. Its purpose is to aid in reducing the 
diversion of PSE-based products for use 
as precursors in the domestic manufacture 
of methamphetamine (Pharmacy Guild of 
Australia 2006). 
A pilot of Project STOP was launched in 
Queensland in November 2005 (Parliamentary 
Joint Committee on the Australian Crime 
Commission 2006). Project STOP was 
included under the Australian National 
Precursor Strategy in 2007 (Ministerial Council 
on Drug Strategy 2008) and introduced 
nationally in 2008 (Ransley et al. 2012).
In practice, all requests for PSE-based 
medications are entered into Project STOP 
(Pharmacy Guild of Australia 2013). The 
pharmacist records the photo-identification 
card number of the customer and the product 
requested, and the database runs a check on 
the number. According to the Pharmacy Guild 
of Australia (PGA; 2013) the ‘match screen’ 
then provides the pharmacist with information 
to help them determine the legitimacy of the 
sale. 
If the customer’s identification number is 
associated with the purchase of at least 
one other PSE-based medication within 
the recommended therapeutic period, the 
pharmacist is able to view that individual’s 
sales pattern for the preceding 100 days 
(PGA 2007). Most cold and flu medications 
containing PSE recommend a dose for adults 
and children over 12 years of two tablets, 
3–4  times per day; that is, a maximum of 
eight tablets per day across three days, with a 
typical box of medication containing 24 tablets 
(equivalent to 720 mg of pseudoephedrine). 
At this point the pharmacist is presented with 
three choices: 
• to allow the sale; 
• to make the sale but record it as a ‘safety 
sale’, indicating the pharmacist has 
concerns about the sale’s legitimacy but 
is uncomfortable about confronting the 
customer; or
• to deny the sale due to concerns about its 
legitimacy (PGA 2007). 
These data are electronically submitted 
to a single central repository managed by 
GuildLink Pty Ltd, collated, and returned to 
pharmacies. 
Impacts of PSE-based medication 
regulation
Australian evaluations of PSE-based 
medication regulations and Project STOP 
are limited (for exceptions, see Ransley et al. 
2012; Siggins Miller 2009; Webster 2013). 
Berbatis, Sunderland, and Dhaliwal (2009) 
examined the impact of Project STOP on 
the number of ATS labs seized between 
1996–97 and 2004–05 in Queensland. 
The authors conclude there were fewer 
lab seizures in Queensland in 2005–06, 
compared with other Australian jurisdictions. 
The study’s major limitation was that, after 
Project STOP was rolled out in Queensland 
in November 2005, its uptake by pharmacies 
increased; its effect on clan lab detection in 
the year ending June 2006, therefore, may 
be underestimated.
The current research explores the impact of 
mandatory electronic recording of PSE-
based medication sales on PSE diversion 
and clan lab detection in Queensland. 
Queensland is the focus of the report, as 
the first jurisdiction in Australia to adopt the 
software; it continues to be the most popular 
state for local methamphetamine production, 
based on the number of clan labs detected  
(Australian Crime Commission 2010; 
Queensland Health et al. 2010).
This study aims to:
• describe the uptake and use of Project 
STOP in Queensland between 2005 and 
2013; 
• examine the utility of Project STOP as 
an aid in reducing the diversion of PSE-
based products for methamphetamine 
production; and 
• assess the impact of Project STOP on clan 
lab detection.
Australian Institute of Criminology  |  3
Figure 1 Number of PSE-based medication transactions, by transaction type
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Method
Description of data sources
PSE transaction data. The Director of 
GuildLink provided the de-identified Project 
STOP data for Queensland for the period of 
8 November 2005 to 31 December 2013. 
Data were cleaned and prepared for analysis. 
The dataset consists of the pharmacy’s 
unique identifier, its postcode, the date and 
time of the transaction, a description of the 
PSE-based medication requested and the 
customer’s unique identifier. The unique 
customer identifier is based on the type of 
identification presented, which must be official 
photo identification such as a driver’s licence 
or passport.
Clan lab detection data. The Queensland 
Police Service (QPS) drug squad provided 
data on clan lab detections between January 
2004 and December 2013. This data was 
related to offences linked to a unique crime 
occurrence where ATS were detected.
Person-of-interest threshold and pseudo-
runners. Pseudo-runners are individuals 
or groups who travel to various pharmacies 
to purchase PSE-based products legally, 
with the intention of diverting them for the 
manufacture of methamphetamine (PGA 
2006). Suspected pseudo-runners were 
identified from Project STOP transaction data 
based on two indicators:
• the Queensland Police Service person-of-
interest flag. The trigger for identifying a 
person of interest, or POI, is determined 
by police in each Australian jurisdiction. In 
some jurisdictions police are sent POI texts, 
while in others data is logged and a POI 
report run; and 
• an individual’s annual transaction history. 
Assuming an adult will suffer 2–4 colds in a 
one-year period, experience symptoms for 
up to two weeks and take the maximum 
daily dose of medication for up to one 
week (Simasek and Blandino 2007), they 
would need up to two and a half boxes of 
medication per cold—roughly 10 boxes 
of cold and flu medication annually. The 
transaction threshold for identifying potential 
pseudo-runners is 21 or more transactions 
per individual in a one-year period, or 
double this conservative estimate of ten 
boxes.
Analysis plan
Standard descriptive statistics and a 
time series analysis using the Joinpoint 
Regression Program were undertaken. 
Joinpoint regression (or piecewise 
regression) is an analytical method used for 
both linear and nonlinear models to identify 
significant changes in trend at one or more 
values of an independent variable, usually 
in a time series (Kim, Fay, Feuer & Midthune 
2000). Joinpoint was used to estimate the 
monthly percent change for both the Project 
STOP transaction and methamphetamine 
clan lab detection data series.
Results
Uptake of Project STOP
When Project STOP was first rolled out 
in Queensland, it was used by 13 of 951 
pharmacies. At the end of 2005, less than 
two months later, it was being used by 350 of 
951 pharmacies. By the end of 2006, 695 of 
Queensland’s 963 pharmacies, or 72 percent, 
had used Project STOP at least once. Over 
90 percent were using Project STOP by 
June 2008; and by the end of 2015, 1,021 
pharmacies—95 percent of pharmacies in 
Queensland—were using Project STOP. 
PSE-based medication transactions 
by transaction type
On average, per month, allowed transactions 
account for 93.9 percent (SD 2.6) of all 
transactions, while safety transactions 
account for 2.1 percent (SD 1.3) and denied 
transactions for 2.4 percent (SD 1.4). 
Transaction trends across the eight-year 
4  |  Australian Institute of Criminology
period vary by transaction type (see Figure 
1). Trend patterns for safety and denied 
transactions are similar; however, the test 
for parallelism was significant (number of 
joinpoints=4, numerator df=9, denominator 
df=176; p<0.001); indicating that the 
estimated models for each series are not 
parallel and therefore cannot be represented 
by a single model.
The trendline for allowed transactions 
suggests one significant deviation across 
the series. The trend for the first section, 
November 2005 to July 2008, was 4.66 (2.91 
to 6.44; p<0.001); for the second section, 
between July 2008 and December 2013, it 
was −0.27 (−0.66 to 0.12; p=0.170). This 
suggests that the estimated monthly rate of 
allowed transactions increased significantly—
by 4.66 percent—between two consecutive 
months until July 2008. However, after this 
period the estimated rate does not differ 
significantly from a flat trend—that is, a rate of 
zero between any two consecutive months.
For safety transactions, there were four 
significant deviations across the series. The 
trend for the first section, November 2005 to 
February 2009, was positive and significantly 
increasing (4.52: 3.68 to 5.37; p<0.001). 
Following this there was a significant increase 
in the series. The trend for the second section, 
February 2009 to June 2009, was 22.38 (0.59 
to 48.89; p<0.05). Between June 2009 and 
July 2010 the trend continued to increase 
significantly, by 5.86 percent between two 
consecutive months (5.86: 4.20 to 7.54; 
p<0.001).
The trend for the fourth section, July 2010 
to October 2010, was decreasing but not 
significant (−17.82: −37.67 to 8.35; p=0.158). 
The trend for the final section was negative 
and significantly decreasing (−1.86: −2.22 
to −1.49; p<0.001). These results suggest 
that the estimated monthly rate of safety 
transactions  increased significantly between 
November 2005 and July 2010, but at 
differing rates. After July 2010 the rate of 
safety transactions substantially decreased; 
between October 2010 and December 2013 
the rate declined significantly, by 1.86 percent.
Like the trend for safety transactions, the 
trendline for denied transactions suggests 
there were four significant deviations across 
the series. Overall, after an initial significant 
decrease of 17.35 percent in the rate of 
denied transactions between two consecutive 
months (−25.22 to −8.65; p<0.001), the 
estimated monthly rate of denied transactions 
significantly increased between July 2006 and 
July 2010, but at differing rates. For example, 
while the estimated monthly rate between 
July 2006 and October 2006 was positive, 
the rate does not significantly differ from a flat 
trend (47.64: −38.36 to 253.62; p=0.375). 
By contrast, the estimated monthly rate of 
denied transactions between December 2008 
and July 2010 significantly increased, by 5.98 
percent, between two consecutive months 
(4.60 to 7.39; p<0.001). After July 2010 
the rate of denied transactions significantly 
decreased by 2.05 percent (−2.35 to −1.75; 
p<0.001).
Suspected pseudo-runner 
purchases
Based on the POI threshold, there have been 
2,499 threshold breaches associated with 
1,289 individuals who presented the same 
identification since the 2005 rollout of Project 
STOP. Of these 1,289 individuals, almost 90 
percent (n=1,154) breached the threshold 
no more than once. For the remaining 135 
individuals, the average number of attempted 
purchases was 3.17 (SE 0.15), with a range of 
between two and 50. The maximum number 
of breaches by any one person was 224; 
however, the mean number of breaches per 
individual was 1.94 (SE 0.04). The annual 
rate of breaches per 10,000 transactions 
was between 3.54 (2011) and 15.13 (2007). 
After 2007 there was a substantial decline in 
the annual percentage of breaches; for the 
last three years there were, on average, 4.23 
breaches per 10,000 transactions.
Across the eight-year period, 75.1 percent 
of all transactions recorded were a 
single transaction per individual per year 
(n=2,382,697); annually, this ranged from 
72 percent (2011) to 84.2 percent (2006; 
see Table 1). The study also examined 
transaction behaviour considered suspect 
according to the conservative regular annual 
transaction estimate of up to 10 transactions 
per year. Combining the data for 11 to 20 
and 21 or more transactions, less than one 
percent (0.67%) of individuals in a given 
year purchased PSE-based medications 
this frequently. Across the eight years this 
percentage ranged from 0.23 percent in 2006 
to one percent in 2010 (see Table 1).
The number of individuals who made 21 or 
more transactions spiked in 2010 (n=648). 
It dropped by 20 percent in 2011 and by 
12 percent in 2012; there was virtually no 
change in 2013. The median number of 
transactions associated with these suspected 
pseudo-runners was typically 26 in any 
given year, equivalent to one transaction per 
fortnight. Across the eight-year period, the 
total number of transactions associated with 
suspected pseudo-runners was 92,405.  For 
those individuals associated with more than 
21 transactions in any one-year period, the 
median number of pharmacies visited during 
the eight-year period ranged from three (in 
2012 and 2013) to 10.5 (in 2006); the eight-
year median was five. The maximum number 
of pharmacies visited in any one-year period 
ranged between 19 in 2013 and 132 in 2007.
Clan lab detections
Figure 2 presents the data recorded by the 
QPS on monthly rates of methamphetamine 
clan lab detections; these are reported per 
100,000 people aged 14 years and over. 
The dashed vertical black line (November 
2005) indicates the introduction of Project 
STOP in Queensland. The red line (June 
2008) indicates the point at which more than 
90 percent of Queensland pharmacies were 
using Project STOP.
The trend for the first section of the series, 
January 2004 July 2008, was negative 
and significantly decreasing (−1.13:−1.82 
to −0.44; p<0.001). Following this, there 
was a significant upturn in the series. The 
trend for the second section, July 2008 to 
August 2009, was 8.62 (2.69 to 14.90; p< 
0.01). The trend for the final section, August 
2009 to December 2013, was decreasing 
but non-significant (−0.29: −0.77 to 0.19; 
p=0.237). These results suggest that, after an 
initial significant decrease between January 
2004 and July 2008, there was a significant 
increase in detections. After April 2009, there 
was a downturn in the trend; but this rate did 
not significantly differ from a flat trend.
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Table 1 Numbers of transactions per individual per year
 Year of transactions
Number of 
transactions
2006 2007 2008 2009 2010 2011 2012 2013 Total
1 116,846 
(84.2)
182,627 
(80.6)
251,420 
(77.3)
253,588 
(74.7)
252,805 
(72.4)
257,368 
(72.0)
246,901 
(73.4)
225,965 
(73.9)
1,790,520 
(75.1)
2 14.510
(10.5)
28,734 (12.5) 45,299 
(13.9)
49,154 
(14.5)
51,699 
(14.8)
54,745 
(15.3)
50,383 
(15.0)
44,816 
(14.6)
339,340 
(14.2)
3–5 6,062 (4.4) 12,804 (5.6) 22,353 
(6.9)
27,458 (8.1) 32,804 (9.4) 34,824 (9.7) 30,518 
(9.1)
26,857 
(8.8)
193,680 
(8.1)
6–10 1,058 (0.8) 2,255 (1.0) 4,419 (1.4) 6,611 (1.9) 8,564 (2.5) 7,984 (2.2) 6,396 (1.9) 6,074 
(2.0)
43,361 
(1.8)
11–20 272 (0.2) 633 (0.3) 1,354 (0.4) 2,232 (0.7) 2,795 (0.8) 2,188 (0.6) 1,665 (0.5) 1,778 
(0.6)
12,917 
(0.5)
21+ 54 (0.0) 128 (0.1) 291 (0.1) 590 (0.2) 648 (0.2) 519 (0.1) 458 (0.1) 461 (0.2) 3,149 (0.1)
Total 138,802 230,181 325,136 339,633 349,315 357,628 336,321 305,951 2,382,967
Figure 2 Rate of detected MA clan labs, January 2004 to December 2013
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Discussion
Does Project STOP reduce the 
diversion of PSE-based 
medications?
The purpose of this study is to evaluate 
the utility of Project STOP in reducing 
the diversion of PSE-based products 
to clan labs. Using time-series analysis, 
the research illustrates an initial sharp 
increase in allowed PSE transactions 
between November 2005 and July 2008, 
when Queensland pharmacies were 
increasingly adopting Project STOP. Allowed 
transactions then plateaued between 
July 2008 and December 2013. These 
findings suggest that since Project STOP 
achieved 90 percent coverage of the state, 
Queensland pharmacies have experienced 
a stable rate of allowed PSE-based 
medication transactions. 
The findings indicate similar trends in rates 
of both safety and denied transactions; 
these increased significantly between July 
2006 and July 2010, then steadily declined 
to the end of the series in December 
2013. It is plausible that following the 
initial period of Project STOP uptake, with 
the majority of pharmacies consistently 
utilising Project STOP between 2005 and 
2010, there has been a reduction in the 
number of individuals attempting to obtain 
PSE-based medication for diversion to 
methamphetamine production.
Trends for suspected pseudo-runners—as 
determined by POI threshold, or who made 
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21 or more transactions in one year—are 
consistent with the safety and denied 
transaction trends. After 2007 there was a 
substantial decline in breaches; for the last 
three years of the study period the average 
rate of breaches was 4.23. Moreover, the 
number of individuals who made 21 or more 
transactions spiked in 2010; it dropped by 
20 per cent in 2011 and by a further 12 per 
cent in 2012, and was virtually unchanged 
by 2013.
The threshold breach data identified 1,289 
individuals considered POI. Using the 21 
or more transactions per year estimate 
identified 3,149 suspected pseudo-runners. 
The large discrepancy in these two numbers 
highlights the possibility that individuals may 
intentionally avoid making purchases during 
the breach threshold period. The threshold 
timeframe should therefore be reviewed, 
to assist police in their investigations of 
pseudo-runners.
Does Project STOP impact clan lab 
detection?
With stable allowed PSE transaction trends 
and declining trends in safety transactions, 
denied transactions and suspected 
pseudo-runner activity, a decline in clan 
lab detections would be expected. This 
research finds the monthly rate of clan lab 
detections decreased significantly between 
January 2004 and July 2008, followed by 
a significant upturn between July 2008 and 
August 2009. After this time, detections 
plateaued to December 2013. Analysis of 
the clan lab detection data does not reflect 
the pattern that could be expected given the 
results of the Project STOP analysis.
Four explanations are offered for the clan lab 
detection trend: the importation of PSE into 
Queensland, changes in cooking methods, 
changes in police practices and a greater 
number of small clan labs.
• The clan lab patterns described may be 
a result of the importation of PSE-based 
medications from other jurisdictions 
(interstate or international). Consequently, 
any observable effect of Project STOP 
on methamphetamine production in 
Queensland may have been masked by 
access to PSE from outside Queensland. 
Between 2005 and 2008 Queensland was 
the only jurisdiction to implement Project 
STOP, so it is highly likely that during 
this period PSE-based medication was 
supplied across state borders. Without 
the adoption of a uniform solution, 
such as Project STOP, to PSE-based 
medication diversion across pharmacies 
in all states, interstate PSE trafficking is 
likely to continue.
• Methamphetamine cooks may have 
changed their cooking practices 
(Ritter et al. 2012). The majority of 
clan labs in Australia have been 
producing methamphetamine using the 
hypophosphorous acid method, which 
requires PSE as a precursor (National 
Drug Research Institute & Australian 
Institute of Criminology 2007); they may 
now be using the phenyl-2-propanone 
(P2P) method, or other methods which 
do not require PSE as a precursor, in 
response to restrictions on PSE-based 
medications (Ritter et al. 2012). This shift 
in cooking method may account for the 
absence of a decline in clan lab detection 
rates. 
• During 2008 the QPS increased education 
and training for recruits, frontline police 
and detectives in the identification, 
detection and investigation of drug 
production offences (Senior Sergeant 
A Frost and Ms S Mayes personal 
communication 2014). Moreover, access 
to Project STOP was expanded to include 
district-level intelligence officers. This 
access allowed regional police to target 
PSE diversion, precursor procurers and 
the manufacture of methamphetamine; it 
also allowed intelligence officers to utilise 
Project STOP for secondary intelligence. 
• Prior to 2008, the majority of clan 
lab seizures in Queensland were of 
small- to medium-scale labs using 
mostly scientific glassware and some 
improvised equipment. In 2008 precursor 
and equipment reporting controls were 
regulated, and there was a consequent 
reduction in the availability of chemicals 
and scientific equipment diverted for 
use. This reduction saw a shift in the 
equipment and scale of drug labs 
seized in Queensland. The QPS started 
to see more single-use improvised lab 
equipment, fashioned from non-controlled 
items, and the use of smaller quantities 
of precursor chemicals. This is likely to 
have contributed to the increase in smaller 
addiction-based labs and the reduction in 
medium-scale labs in Queensland.
Conclusion and implications
The findings of the report show Project 
STOP is used by 95 percent of Queensland 
pharmacies. It has demonstrated its 
utility for pharmacists in determining the 
legitimacy of customer requests for PSE-
based medication and, if used appropriately 
and consistently, can reduce the amount of 
PSE-based medication leaving pharmacies 
for methamphetamine production. 
The findings of this study support anecdotal 
evidence reported by others (Ritter et al. 
2012) that the problem of pseudo-runners 
appears to be declining in response to 
restrictions on the availability of PSE-based 
medications. However, this reduction does 
not appear to have translated to a decline in 
clan lab detections. Queensland continues 
to have the largest number of clan labs 
in Australia. Evidence from this research 
highlights the challenges of trying to curtail 
methamphetamine production in Australia.
The findings also highlight the limitations 
of a single POI police flag, with evidence 
showing that active pseudo-runner 
behaviour has not been flagged as a POI 
breach. Further research to develop a 
series of algorithms that can be applied 
to Project STOP data to better identify 
POIs is necessary. Better identification 
will allow more suspect purchasers to be 
identified. This intelligence could inform 
police investigations and aid pharmacists in 
identifying suspect purchasing.
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